Literature DB >> 33465495

Peripheral blood hsa-circRNA5333-4: A novel biomarker for myasthenia gravis.

Jie Lv1, Lu Ren2, Sensen Han1, Jing Zhang1, Xue Zhao1, Yingna Zhang1, Hua Fang1, Linyuan Zhang1, Haonan Yang1, Shumin Wang1, Junhong Yang3, Xinzheng Cui4, Qingyong Zhang4, Yunke Zhang3, Feng Gao5.   

Abstract

In this study, the potential of specific Circular RNAs (circRNAs) as novel peripheral blood biomarkers for myasthenia gravis (MG) was explored. We analyzed circRNAs in the peripheral blood of three normal controls and three MG patients using RNA microarray. Candidate circRNAs were validated in three independent cohorts by Quantitative Real-time polymerase chain reaction (qPCR). Eleven differentially expressed circRNAs were initially identified and four were confirmed in the first independent cohort. Hsa_circ_0076490 and hsa-circ_5333-4 had the largest areas under the curve (AUCs) of the receiver operating characteristics (ROC) and were validated in the second cohort. In the third cohort, hsa-circRNA5333-4 had a larger AUC: 0.864 (95% confidence interval [CI] = 0.801-0.928, P < 0.001), a stronger correlation with the Quantitative Myasthenia Gravis Score (qMG): r = 0.505 (P < 0.001) and was correlated with gender and acetylcholine receptor antibody levels (P < 0.05). So hsa-circRNA5333-4 represents a novel biomarker for the diagnosis and monitoring of MG.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Circular RNA (CircRNA); Hsa-circRNA5333-4; Myasthenia gravis (MG); Peripheral blood

Year:  2021        PMID: 33465495     DOI: 10.1016/j.clim.2021.108676

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  1 in total

Review 1.  Long Non-Coding RNAs in the Cell Fate Determination of Neoplastic Thymic Epithelial Cells.

Authors:  Alessia Iaiza; Claudia Tito; Federica Ganci; Andrea Sacconi; Enzo Gallo; Silvia Masciarelli; Giulia Fontemaggi; Alessandro Fatica; Enrico Melis; Vincenzo Petrozza; Federico Venuta; Mirella Marino; Giovanni Blandino; Francesco Fazi
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.